Prosecution Insights
Last updated: May 29, 2026

BOSTON MEDICAL CENTER CORPORATION

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
3
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (33%)
2
Unknown (67%)

Rejection Statute Mix

BucketCases
§112 only1 (33%)
No statute on record2 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
33% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BERTOGLIO, VALARIE E 1 64.2% +29.6%
COUNTS, GARY W 1 58.9% +29.3%
HOFFA, ANGELA MARIE 1 67.3% +27.1%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17120950 TISSUE MARKERS HOFFA, ANGELA MARIE 169d overdue
18033222 METHODS FOR IDENTIFYING AND TREATING ANTIBODY-MEDIATED ACQUIRED PRIMARY OR RECURRENT IDIOPATHIC NEPHROTIC SYNDROME COUNTS, GARY W 26d
18456148 HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION BERTOGLIO, VALARIE E

Top Art Units

Art UnitApps
1632 1
1678 1
3799 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18456148 HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION BERTOGLIO, VALARIE E 1632 Other Non-Final OA Pending Aug 25, 2023
18033222 METHODS FOR IDENTIFYING AND TREATING ANTIBODY-MEDIATED ACQUIRED PRIMARY OR RECURRENT IDIOPATHIC NEPHROTIC SYNDROME COUNTS, GARY W 1678 §112 Non-Final OA 26d Pending Apr 21, 2023
17120950 TISSUE MARKERS HOFFA, ANGELA MARIE 3799 Non-Final OA 169d overdue Pending Dec 14, 2020

Managing BOSTON MEDICAL CENTER CORPORATION's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month